MR 107A 02
Alternative Names: MR-107A-02; MR-107A-02 oral tabletLatest Information Update: 25 Jan 2024
At a glance
- Originator Mylan Specialty
- Class Analgesics; Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 29 Dec 2023 Phase-III clinical trials in Postoperative pain in USA (PO) (NCT06215859)
- 29 Dec 2023 Mylan Specialty initiates enrolment in a phase III trial for Postoperative pain in USA (PO) (NCT06215820)
- 20 Jun 2022 Mylan Specialty and Viatris completes the phase II trial in Postoperative pain in USA (PO) (NCT05317312)